Furthermore, the similarity in glycemic control and kidney function changes for both the SGLT2 inhibitor and GLP-1 RA groups implied that mechanisms possibly underlying the lower incidence of anemia from SGLT2 inhibitor use are independent of these factors. The gene discussed is SLC5A2; the disease is anemia.